Menu
Oncimmune
Oncimmune has developed a powerful new approach to the early diagnosis of primary cancer, cancer recurrence and the clinical management of cancer.
Healthcare: Diagnostics – cancer
School of Medicine
Profile
Oncimmune has developed a powerful new approach to the early diagnosis of primary cancer, cancer recurrence and the clinical management of cancer.
The technology is based on serum assays that detect auto-antibody formation to known cancer antigens with the clinical utility of early diagnosis of cancer.
This breakthrough is currently applied to lung cancer through the development of a blood test EarlyCDT®, but will be extended to the detection of other common cancers such as breast, colorectal, ovarian and prostate.
The company is based in customised laboratory and office space at Nottingham City Hospital, and began trading on AIM in May 2016.
News and press releases
Our sale of shares represents a significant return on our original investment in Oncimmune and the company is an exemplar of what can be done when a technology is successfully spun out from the University of Nottingham. It has been a pleasure to see Oncimmune grow into a leading early cancer detection company that is already saving lives and is on track to save many more. We look to the future with confidence as the company has the management and strategy in place to deliver value and we are delighted to retain a significant shareholding
Dr Andrew Naylor
Chief executive – Nottingham Technology Ventures
@OncimmuneECDT on Twitter
Oncimmune Holdings plc recently announced a collaboration with @SiemensHealth aimed at improving malignancy risk assessment of Indeterminate Pulmonary Nodules ("IPNs"). Read more: http://bit.ly/3KkJ3hy #EarlyCDT #Autoantibodies #LungCancer #LungNodules
#FridayReads This review on T cell response in #autoimmunity and #cancer highlights interplay from these two diseases and how they can provide answers to improve the application, efficacy, and management of #immunotherapies #biomarkers #autoantibodies
http://bit.ly/3lIJOXz
BIVDA member @OncimmuneECDT received a Queen’s Award for Enterprise in Innovation 2022 by Sir John Peace, the Lord-Lieutenant of Nottinghamshire, today.
What a great achievement, congratulations from all at BIVDA!
ABHI member @OncimmuneECDT received a Queen’s Award for Enterprise in Innovation 2022 by Sir John Peace, the Lord-Lieutenant of Nottinghamshire, today.
What a great achievement, congratulations from all at ABHI!
We're thrilled to have received the @TheQueensAwards for Enterprise in Innovation 2022 awarded by Sir John Peace, the @Lord_Lt_Notts at our Nottingham laboratories! Thanks to all our staff who have made this great achievement possible! @LordMayorNottm #TeamOncimmune
Are you attending #IO360nyc ? Make sure to meet our team at booth 18. Learn more about the #ImmunoINSIGHTS platform and how it provides relevant immune #biomarker insights for your clinical programs. #celltherapy #cancerresearch #clinicaltrials #immunooncology
Nice review on the interplay of immune #checkpointinhibitors ICI therapies #toxicities #cancer. #BCells & #antibodies against autologous antigens (#autoantibodies) advances as emerging #biomarkers to predict immune-related #adverseevents #irAEs
Checkpoint inhibitor immune-related adverse events: A focused review on autoantibodies and B cells as biomarkers, advancements and future possibilities
The use of immune checkpoint inhibitors (ICIs) has evolved rapidly with unprecedented treatment benefits being obtained for cancer patients, including...
bit.ly
We’re excited to be exhibiting on Feb 7-10th at the #IO360nyc ! Come and meet with our team at booth #18 𝑾𝒆’𝒓𝒆 𝒍𝒐𝒐𝒌𝒊𝒏𝒈 𝒇𝒐𝒓𝒘𝒂𝒓𝒅 𝒕𝒐 𝒔𝒆𝒆 𝒚𝒐𝒖 𝒕𝒉𝒆𝒓𝒆! #Oncimmune #ImmunoINSIGHTS #biomarkers
#cancerimmunotherapy #clinicaltrials #precisiononcology
Gallery
